HyperFlux™ PRO Plus now available in Europe
13 October 2016 | By Tornado Spectral Systems
Full Raman spectroscopy system joins Tornado Spectral Systems’ stand-alone spectrometers...
List view / Grid view
News
Ablynx starts Phase III follow-up aTTP study
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Acquired TTP is an acute, ultra-rare, life-threatening blood clotting disorder in which uncontrolled platelet aggregation and microclot formation cause...
Neurocrine’s Tardive Dyskinesia drug application accepted for FDA priority review
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for Neurocrine Biosciences‘ Ingrezzatm (valbenazine) for the treatment of tardive dyskinesia. The application has been given a prescription drug user fee act (PDUFA) target action date of April 11, 2017. A Priority Review…
Reduced risk of NSCLC death seen in Boehringer Ingelheim’s head-to-head trial
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The trial investigated overall survival and the reduction in risk of death (14%) was observed for patients treated with afatinib versus gefitinib...
Particle Works offers bespoke microencapsulation for drug development
12 October 2016 | By Particle Works
Particle Works – the nano- and microstructured material specialist – provides microencapsulation services for drug development applications, including controlled drug release, solubility enhancement or targeted drug delivery...
FDA grants priority review for Genmabs’ daratumumab to treat relapsed multiple myeloma
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA has assigned a prescription drug user fee act (PDUFA) target date of February 17, 2017 to take a decision on daratumumab in this indication...
Patient overall survival still strong three years after Novartis’ melanoma trial
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
45% of patients receiving the combination of Tafinlar + Mekinist (95% CI, 39.1%-49.8%) compared with 31% of patients who received vemurafenib monotherapy...
NICE recommends Apremilast for treating psoriatic arthritis
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has released draft guidance recommending Apremilast for the treatment of psoriatic arthritis in adults. This appraisal was a rapid review of the NICE technology appraisal guidance published in December 2015. It focused on cost-effectiveness analyses using a patient access scheme agreement, which provides apremilast at…
Alexza granted FDA approval of Adasuve sNDA to treat schizophrenia
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Administration of Adasuve results in rapid absorption of loxapine, with a maximum plasma concentration achieved in approximately 2 minutes...
Daiichi Sankyo Phase 1 HER2-targeting antibody drug safe and effective to treat breast cancer
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
DS-8201a is an investigational antibody drug conjugate comprised of a humanised anti-HER2 antibody attached by a peptide linker to a novel topoisomerase...
Scotland speeds ahead to deliver breakthrough immunotherapy to lung cancer patients
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
This recommendation means that patients in Scotland will become the first in the UK to be treated with nivolumab on the NHS...
Novartis’ HR+/HER2- advanced breast cancer trial gives superior progression-free survival
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The results demonstrate that LEE011 plus letrozole reduced the risk of death or progression by 44%. The combination significantly improved PFS across...
Sophia Genetics’ data-driven technology gives actionable cancer information
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The new data-driven tech, OncoPortal, improves the diagnosis and treatment of solid tumours and haematological malignancies for patients around the world...
‘Game-changing’ immunotherapy doubles head and neck cancer survival
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer...
Vtesse doses first patient in Phase 2b/3 Niemann-Pick Type C1 trial
7 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The VTS-270 clinical program is aimed at treating the neurological disease that is the primary cause of child mortality with Niemann-Pick Type C1 disease...
